I currently hold two positions at the Karolinska Institute (KI). I am a team leader in the larger group of Olli Kallioniemi, and group leader of the biology team at Chemical Biology Consortium Sweden (CBCS), a national infrastructure at SciLifeLab.
Our ultimate goal is to promote the move away from one-size-fits-all therapies to improve patient outcome through treatment stratification and tailoring. Despite advances in precision medicine diagnostics, there are still major opportunities to improve individualized patient care throughout the entire health care value chain, spanning from preclinical studies in drug discovery through to the design of precision diagnostics. Research in my team focuses on challenges central to these fields, developing technologies and disease models that enable direct measurement of patient response to treatment ex vivo and investigation of the molecular determinants of drug response. Such methods and model systems are critical to improve the study of disease biology, identify and validate new drug targets, correctly prioritize drug candidates for clinical trials, uncover potential biomarkers for future patient stratification and have even recently been used successfully as diagnostics to match patients to effective treatments.
Our translational research group and surrounding team of clinicians and experts has two major themes as described below united by the main goal of investigating drug response and biomarkers in primary patient cells and other near-patient models of disease.
I co-organize the Overview Course in Cancer Drug Discovery.
2013-2015: PostDoc; Broad Institute of Harvard and MIT
2007-2012 PhD; KTH Royal Institute of Technology, Stockholm, Sweden
2005-2007 MSc; California Institute of Technology, Pasadena, CA, USA
2001-2005 BA; Macalester College, St. Paul, MN, USA